Biostage Inc  

(Public, OTCMKTS:BSTGD)   Watch this stock  
Find more results for NASDAQ:BSTG
+0.10 (3.85%)
Jan 19 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 2.40 - 2.87
52 week 0.60 - 17.42
Open 2.66
Vol / Avg. 18,342.00/27,305.00
Mkt cap 107.43M
P/E     -
Div/yield     -
EPS -10.34
Shares 1.99M
Beta -0.24
Inst. own 6%
Nov 10, 2017
Q3 2017 Biostage Inc Earnings Release (Estimated)

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -14120.73%
Operating margin - -14787.80%
EBITD margin - -14234.15%
Return on average assets -360.87% -171.45%
Return on average equity -1480.66% -229.83%
Employees 27 -
CDP Score - -


84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-774-2337300 (Phone)
+1-774-2337302 (Fax)

Website links


Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
James J. McGorry Chief Executive Officer, Director
Age: 59
Thomas McNaughton Jr. Chief Financial Officer
Age: 54
Harout DerSimonian Chief Scientific Officer
David M. Green Director
Age: 50
Blaine H Mckee Ph.D. Director
John J. Canepa Independent Director
Age: 59
Thomas H. Robinson Independent Director
Age: 58